HIV coinfection with hepatitis c: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
(No difference)

Revision as of 21:48, 23 February 2012

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

HIV coinfection with hepatitis c On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV coinfection with hepatitis c

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV coinfection with hepatitis c

CDC on HIV coinfection with hepatitis c

HIV coinfection with hepatitis c in the news

Blogs on HIV coinfection with hepatitis c

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for HIV coinfection with hepatitis c

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

Recommendations for Diagnosis and Treatment of Persons with HIV Coinfection: AASLD Practice Guidelines 2009[1]

1. Anti-HCV testing should be performed in all HIV-infected persons (Class I, Level B).

2. HCV RNA testing should be performed to confirm HCV infection in HIV-infected persons who are positive for anti-HCV, as well as in those who are negative and have evidence of unexplained liver disease (Class I, Level B).

3. Hepatitis C should be treated in the HIV/HCV co-infected patient in whom the likelihood of serious liver disease and a treatment response are judged to outweigh the risk of morbidity from the adverse effects of therapy (Class I, Level A).

4. Initial treatment of hepatitis C in most HIV infected patients should be peginterferon alfa plus ribavirin for 48 weeks at doses recommended for HCV mono-infected patients (Class I, Level A).

5. When possible, patients receiving zidovudine (AZT) and especially didanosine (ddI) should be switched to an equivalent antiretroviral agent before beginning therapy with ribavirin (Class I, Level C).

6. HIV-infected patients with decompensated liver disease (CTP Class B or C) should not be treated with peginterferon alfa and ribavirin and may be candidates for liver transplantation (Class IIa, Level C).

References

  1. Swan T, Curry J (2009). "Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users". Hepatology (Baltimore, Md.). 50 (1): 323–4, author reply 324–5. doi:10.1002/hep.23077. PMID 19554546. Retrieved 2012-02-21. Unknown parameter |month= ignored (help)

Template:WS Template:WH

References

Template:WS Template:WH